Anil Tulpule, MD

Dr. Tulpule began his medical education and career in his native India before coming to Southern California on a fellowship in medical oncology at the Keck School of Medicine. After completion of his first USC fellowship, Dr. Tulpule was granted an additional fellowship in the Department of Hematology where he is currently holds an assistant professor appointment. Dr. Tulpule remains active in AIDS research, including a ten year affiliation with the government sponsored AIDS-Related Malignancy Working Group at the National Cancer Institute.

He has received over fifteen research grants on a number of hematology related subjects and his work has been published in many noted medical journals. Dr. Tulpule is a member of the LAC+USC Medical Center’s Internal Review Board and has a role in determining the ethical implications of the center’s research studies. His dedication to ethical practices also includes a membership of USC Norris Comprehensive Cancer Center’s Patient’s Rights Committee.

• Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry Acta Haematol. 2020; 143(1):40-50. . View in PubMed
• Cardiac birth defects in a twin infant born to a woman with chronic myeloid leukemia on dasatinib J Oncol Pharm Pract. 2019 Apr; 25(3):699-702. . View in PubMed
• The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study Cancer. 2019 05 01; 125(9):1507-1517. . View in PubMed
• Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma J Clin Oncol. 2017 Nov 01; 35(31):3538-3546. . View in PubMed
• A prospective cohort study of patients with peripheral T-cell lymphoma in the United States Cancer. 2017 Apr 01; 123(7):1174-1183. . View in PubMed
• Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States Clin Lymphoma Myeloma Leuk. 2017 04; 17(4):193-200. . View in PubMed
• p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study Am J Clin Pathol. 2014 Apr; 141(4):593-604. . View in PubMed
• Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047 J Clin Oncol. 2013 Jan 01; 31(1):58-64. . View in PubMed
• Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity Lancet Oncol. 2010 Dec; 11(12):1149-59. . View in PubMed
• Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy Cancer. 2010 Aug 15; 116(16):3969-77. . View in PubMed
• Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma Blood. 2010 Jul 15; 116(2):297-305. . View in PubMed
• KSHV-induced notch components render endothelial and mural cell characteristics and cell survival Blood. 2010 Jan 28; 115(4):887-95. . View in PubMed
• Bendamustine therapy in chronic lymphocytic leukemia Expert Opin Pharmacother. 2009 Jul; 10(10):1687-98. . View in PubMed
• Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma J Clin Oncol. 2008 Sep 20; 26(27):4473-9. . View in PubMed
• Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies Cancer. 2006 Oct 15; 107(8):1909-17. . View in PubMed
• Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma Clin Lymphoma Myeloma. 2006 Jul; 7(1):59-64. . View in PubMed
• Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy J Clin Oncol. 2006 Apr 10; 24(11):1712-9. . View in PubMed
• Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy J Clin Oncol. 2005 Nov 20; 23(33):8477-82. . View in PubMed
• Multidrug resistance in AIDS-related lymphoma Curr Opin Oncol. 2005 Sep; 17(5):466-8. . View in PubMed
• AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy J Clin Oncol. 2005 Jul 01; 23(19):4430-8. . View in PubMed
• Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi’s sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team J Clin Oncol. 2005 Feb 10; 23(5):990-8. . View in PubMed
• Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium Blood. 2005 Feb 01; 105(3):1310-8. . View in PubMed
• Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin’s lymphoma: results of therapy and correlates of response J Clin Oncol. 2004 Jul 01; 22(13):2662-70. . View in PubMed
• Treatment of AIDS related non-Hodgkin’s lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study Invest New Drugs. 2004 Jan; 22(1):63-8. . View in PubMed
• Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma Cancer. 2002 Jul 01; 95(1):147-54. . View in PubMed
• Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection Cancer. 2002 Mar 01; 94(5):1500-6. . View in PubMed
• Multidrug resistance (MDR-1) expression in AIDS-related lymphomas Leuk Res. 2002 Feb; 26(2):121-7. . View in PubMed
• High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin’s lymphoma J Acquir Immune Defic Syndr. 2001 Dec 15; 28(5):416-21. . View in PubMed
• Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi’s sarcoma Clin Cancer Res. 2001 Sep; 7(9):2693-702. . View in PubMed
• Clinical aspects and management of AIDS-related Kaposi’s sarcoma Eur J Cancer. 2001 Jul; 37(10):1288-95. . View in PubMed
• Evolving characteristics of AIDS-related lymphoma Blood. 2000 Dec 15; 96(13):4084-90. . View in PubMed
• Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist Blood. 2000 Nov 01; 96(9):3188-94. . View in PubMed
• Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin’s disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149) J Acquir Immune Defic Syndr. 2000 Aug 15; 24(5):444-50. . View in PubMed
• Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi’s sarcoma J Clin Oncol. 2000 Feb; 18(4):716-23. . View in PubMed
• AIDS-related lymphoma Blood Rev. 1999 Sep; 13(3):147-50. . View in PubMed
• Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi’s sarcoma J Clin Oncol. 1999 Jun; 17(6):1876-83. . View in PubMed
• Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin’s lymphoma Cancer. 1998 Dec 01; 83(11):2370-6. . View in PubMed
• Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi’s sarcoma J Clin Oncol. 1998 Oct; 16(10):3369-74. . View in PubMed
• Emerging treatments for epidemic (AIDS-related) Kaposi’s sarcoma Curr Opin Oncol. 1998 Sep; 10(5):413-21. . View in PubMed
• AIDS-Related malignancies Prim Care. 1998 Jun; 25(2):473-82. . View in PubMed
• Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi’s sarcoma J Natl Cancer Inst. 1997 Dec 03; 89(23):1797-802. . View in PubMed
• Treatment of epidemic (AIDS-related) Kaposi’s sarcoma Curr Opin Oncol. 1997 Sep; 9(5):433-9. . View in PubMed
• Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial J Clin Oncol. 1997 Mar; 15(3):1094-103. . View in PubMed
• Interleukin-4 in the treatment of AIDS-related Kaposi’s sarcoma Ann Oncol. 1997 Jan; 8(1):79-83. . View in PubMed
• The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi’s sarcoma N Engl J Med. 1996 Oct 24; 335(17):1261-9. . View in PubMed
• Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphomaEffect on human immunodeficiency virus and serum interleukin-6 levels over time. Cancer. 1996 Aug 01; 78(3):517-26. . View in PubMed
• Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin J Clin Oncol. 1995 Apr; 13(4):996-1003. . View in PubMed
• Intraperitoneal 5-fluoro-2′-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study Cancer Chemother Pharmacol. 1995; 37(1-2):32-8. . View in PubMed
• Intraperitoneal 5-fluoro-2′-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical tolerance Invest New Drugs. 1994; 12(3):197-206. . View in PubMed
• All-trans retinoic acid for the treatment of AIDS-related Kaposi’s sarcoma: results of a pilot phase II study Leukemia. 1994; 8 Suppl 3:S26-32. . View in PubMed

• Lenz, Heinz-Josef
• Gill, Parkash
• Matsuo, Koji